Hypofractionated IMRT

RADIATION4 trials

Sponsors

Istituto Clinico Humanitas, Zhejiang Cancer Hospital, Memorial Sloan Kettering Cancer Center, Samsung Medical Center

Conditions

Endometrial CancerGlioblastoma MultiformeGliomaUterine Cervical Neoplasms

Phase 2

Trial of Hypofractionated Intensity Modulated Radiation Therapy With Temozolomide and Granulocyte-macrophage Colony-stimulating Factor for Patients With Newly Diagnosed Glioblastoma Multiforme

Zhejiang Cancer HospitalGlioblastoma Multiforme

Start: 2016-01-31Target: 41Updated: 2016-01-26

Radiation and TSR-042 (Dostarlimab) in People With Endometrial Cancer After They Receive Surgery

RecruitingNCT04774419

Memorial Sloan Kettering Cancer CenterEndometrial Cancer

Start: 2021-04-02End: 2027-02-01Target: 62Updated: 2026-02-03

Phase 3

Comparison of Conventional and Hypofractionated IMRT in High-Risk Cervical Cancer Post-Radical Hysterectomy

RecruitingNCT06509724

Samsung Medical CenterUterine Cervical Neoplasms

Start: 2024-07-19End: 2032-12-31Target: 248Updated: 2024-07-26

Unknown Phase

Hypofractionated IMRT With Temozolomide for HGG

CompletedNCT02082119

Istituto Clinico HumanitasGlioma

Start: 2013-07-31End: 2016-05-31Updated: 2020-10-12

Related Papers

Postoperative conventional versus hypofractionated intensity-modulated radiation therapy with concurrent chemotherapy in cervical cancer: a prospective multicenter randomized phase III trial (POHIM_P3 trial)

Journal of Gynecologic Oncology2025-07-181 citations

Granulocyte-macrophage colony-stimulating factor for newly diagnosed glioblastoma.

2025-03-15